Stock Markets March 31, 2026

Tate & Lyle's CEO Nick Hampton Expected to Exit After Eight Years

Company has been searching for a successor as shares and guidance have weakened

By Priya Menon
Tate & Lyle's CEO Nick Hampton Expected to Exit After Eight Years

Nick Hampton, who became Tate & Lyle's CEO in April 2018 after joining the company as CFO in 2014, is reportedly preparing to step down after eight years leading the food ingredients supplier. The company has engaged headhunters to identify a replacement and a departure could occur as soon as this year. Tate & Lyle's shares have fallen sharply under Hampton's tenure and the company recently signalled a modest revenue and core profit decline for the fiscal year ending March 31.

Key Points

  • Nick Hampton is preparing to step down after eight years at Tate & Lyle, with the company engaging headhunters to find a successor - sectors impacted include food ingredients and consumer staples.
  • Hampton joined Tate & Lyle as CFO in 2014 and became CEO in April 2018; under his leadership the stock has fallen about 34% since his appointment and dropped 42.3% in 2025 - markets and investors are affected.
  • The company forecast in February that revenue and core profit would decline by a low-single-digit percentage for the fiscal year ending March 31 - financial results affect corporate clients and supplier relationships in the food and beverage sector.

Nick Hampton, the chief executive officer of Tate & Lyle, is preparing to leave the company after an eight-year stretch in senior roles, industry sources told Sky News. The food ingredients group has been retaining executive search firms for several months to find a successor, and a transition could take place as early as this year.

Hampton first joined Tate & Lyle in 2014 as chief financial officer and was elevated to the chief executive role in April 2018. Since his elevation to CEO, the company’s shares have underperformed, losing roughly 34% of their value since his appointment. The stock experienced a particularly sharp drop in 2025, falling 42.3% during the year.

Earlier this year, Tate & Lyle provided guidance for its fiscal year ending March 31 that pointed to a contraction in both revenue and core profit. In February the company said it expects these measures to decline by a low-single-digit percentage over the fiscal year.

As a major supplier of ingredients to consumer brands, Tate & Lyle is known in part for providing the ingredient behind Splenda, a non-sugar sweetener used in products such as Diet Coke and other sugar-free beverages. The company's performance and leadership stability are therefore of interest to food and beverage customers as well as to investors tracking consumer staples and ingredient supply chains.

The reported search for a new chief executive follows months of engagement with headhunters. Details about candidates, timing, or a formal announcement have not been disclosed. The company’s guidance and recent share-price moves were the only financial specifics provided in its public statements referenced in this report.

With Hampton potentially departing this year, stakeholders will be watching for an appointment that addresses market concerns signalled by the recent share decline and the guidance for lower revenue and core profit. Until a successor is named and a handover is confirmed, uncertainty about leadership and near-term financial trajectory will remain.

Risks

  • Leadership uncertainty - the timing and choice of a new CEO are unresolved, which could affect strategic direction for the food ingredients and consumer staples sectors.
  • Weak near-term financial outlook - the company has guided to a low-single-digit decline in revenue and core profit for the year ending March 31, creating earnings and cash-flow uncertainty for investors and counterparties.
  • Share-price volatility - a 34% decline since Hampton's appointment and a 42.3% fall in 2025 highlight market sensitivity to Tate & Lyle's performance and could influence capital access or investor confidence in the markets sector.

More from Stock Markets

Investors May Be Overreacting to AI Threats Facing Contract Research Firms, Experts Say Mar 31, 2026 Meta Expands Ray-Ban Prescription Smart-Glass Line with Two New Models Mar 31, 2026 Insider Moves: Large Purchases at Sabre, AdaptHealth, Iperionx and Lemonade Countered by Significant Executive Sales Mar 31, 2026 Unilever to Combine Longstanding Food Division with McCormick in $44.8 Billion Deal Mar 31, 2026 Dimon Says Markets Will Stay on Edge Until Iran Conflict Is Resolved Mar 31, 2026